key: cord-0740475-n8xkugrt
authors: Vermeersch, Pieter; André, Emmanuel
title: How the European In Vitro Diagnostic Regulation could negatively impact the European response to the next pandemic: an urgent call for action before May 2022
date: 2021-05-09
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.05.009
sha: 95742797861d6534b08cd2e800027dd866fa42df
doc_id: 740475
cord_uid: n8xkugrt

The Corona Virus Disease 2019 (COVID-19) pandemic has demonstrated that the ability for laboratories to quickly set up and implement labdeveloped tests (LDTs) is essential to respond to an emerging health crisis. The Regulation on in vitro diagnostic medical devices (IVDR) could, however, profoundly impact our ability to respond to a future pandemic since the IVDR could significant restrict the use of LDTs. We address using the example of the current pandemic a number of LDT implementing issues problems which should be addressed. We conclude that the COVID-19 pandemic illustrates that commercial tests cannot cover all patient needs under any given circumstance and that sufficient degrees of freedom for laboratories to ensure their expertise to develop and implement LDTs ultimately benefit European citizens.

The revised EU regulatory framework with regard to medical devices has been published in 1 2017. The new European regulation 2017/745 on medical devices and european regulation 2 2017/746 on in vitro diagnostic (IVD) medical devices came into force on May 25 th 2017 and 3 will replace the three existing medical device directives (93/42/EEC, 98/79/EC and 4 90/385/EEC) [1] . The new regulations will come into application in May 2021 for medical 5 devices and May 2022 for in vitro diagnostic medical devices. A regulation is a legal act of 6 the European Union which immediately comes into force as law in all member states 7 simultaneously. 8

The impact of the new IVD regulation cannot be underestimated since this regulation "lays 9 down rules concerning the placing on the market, making available on the market or putting 10 into service of in vitro diagnostic medical devices for human use and accessories for such 11 devices in the Union" [1] . A Dutch study on the registered devices in the Netherlands 12 estimated that 84% of the IVD tests will need to be certified by a Notified Body under the 13 new IVD regulation compared to only 7% under the old IVD directive [2]. Another major 14 change is that the general safety and performance requirements in annex I of the IVD 15 regulation will also apply to lab-developed tests (LDT), also called in-house tests, which are 16 not put on the market. This situation illustrates a profound weakness of the IVD regulation in the context of an 62 emerging global health threat. While laboratories are forbidden to use LDTs when an obligation to make sure that there is adequate supply to fulfill the needs of patients. It 65 would therefore be required that the regulatory framework is adapted to allow laboratories 66 to develop an LDT in case of inadequate supply at the international level and use the LDT 67 during a predefined time period irrespective of the later availability of commercial CE-IVD 68 assays. If laboratories will be forced to replace their LDT as soon as a CE-IVD assay becomes 69 available on the market, they will most likely never develop an LDT. Availability during a 70 pandemic should be assessed at the global level to avoid recurrent shortages worldwide, 71 particularly in lower resource countries. 72

Finally, it would have been unwise for Charité to make the protocol of their LDT publicly 73 available since the IVD regulation does not provide any protection for the inventor or 74 inventions which are in the public domain. Any commercial company will be allowed to 75 register a test and force the inventing institution to buy its own test. The direct 76 consequence could therefore be that publicly-funded clinical and research laboratories 77 might limit the sharing of their findings and protocols, what would be in opposition to 78 current demands of EU funding agencies and would negatively impact the overall capacity of 79

European laboratories to rapidly respond to emerging diseases. Finally, increased regulatory 80 oversight of LDTs could also result in a slower response to a future pandemic [7] . 81

These problems all stem from the fact that the IVD regulation was pushed by manufacturers 82 of in vitro diagnostics and approved by the European parliament without careful assessment 83 of the impact on the overall knowhow and responsiveness of our European healthcare 84 systems. As part of the ongoing plans aiming to consolidate our preparedness for the 85 ongoing and future pandemics, the European Commission should urgently address the 86 diagnostic tests offered to European citizens and beyond. 96

The ultimate goal of the IVD regulation should be to guarantee the safety, clinical 97 effectiveness, and availability of medical laboratory tests to European citizens. Decisions 98 regarding the use of LDTs should take into account the downstream consequences for 99 patient care such as the essential role of LDTs in adapting technologies to better respond to 100 emerging or neglected health problems such as pandemics and rare diseases. The IVD 101 regulation currently considers laboratory tests as simple commodities in a free market 102

where market mechanisms will correct any imbalances, a concept that cannot be applied in 103 the context of a global health emergency. The COVID-19 pandemic has illustrated that 104 market mechanisms and commercial tests cannot cover all patient needs under any given 105 circumstance and that sufficient degrees of freedom for laboratories to develop and 106 implement LDTs will ultimately benefit European citizens. 107 108 109 110 111

126 on in vitro diagnostic medical devices and repealing directive 98/79/EC and Commission 127 Decision

European IVD classification rules on the notified body involvement. A study on the IVDs 130 registered in the Netherlands

The new IVD Regulation 2017/746: a case 132 study at a large university hospital laboratory in Belgium demonstrates the need for 133 clarification on the degrees of freedom laboratories have to use lab-developed tests to 134 improve patient care

Detection of 136 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Laboratory 139 readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30

Testing in a Pandemic -Improving Access

Lessons from the 145 Belgian experience with regulatory control during the COVID-19 pandemic for the 146 implementation of the European IVD regulation 2017/746